ASPET

10/19/2026

Time is running out to submit your research to this upcoming collection in Molecular Pharmacology, "2025 New Frontiers in GPCR Signaling: Emerging Investigator Highlights!"

This special collection will celebrate the world-leading research showcased by attendees of the 5th Transatlantic ECI GPCR Symposium, a free online event organized for early-career investigators by early-career investigators to foster transatlantic knowledge exchange and collaborations within the GPCR community.

Submit your work by October 31, 2026! Learn more at: https://ow.ly/wp8950ZHH8s

10/19/2026

Abel B. Daartey, PharmD, a Doctoral Fellow at St. John's University, shares how ASPET's sponsorship of the ASBMB Art of Science Communication Course helped him turn self-consciousness into confidence. His experience highlights the power of practice, feedback, and analogy in helping scientists connect their work with audiences beyond the lab.

🔗 https://thepharmacologist.org/featured-sep-2026/

10/16/2026

New discussions are happening now in your ASPET member community:
- As a student just starting out in the field, I'd love to learn more about the different areas of pharmacology. What experiences helped you explore different paths?
- How does your institution handle overhead costs for PhD programs?
Join the conversation or start your own at https://connect.aspet.org/

10/16/2026

Submit your research by December 30 for JPET's upcoming collection, "Peptide-Based Therapeutics for Tumor Immunomodulation."

Original research highlighting design and development of peptide-based therapeutics for tumor microenvironment modulation along with tumor targeting, drug delivery, nanotherapeutics and imaging in cancer research will be considered for this section. Manuscripts demonstrating peptide-based therapeutics (including repurposed peptide-based drugs) as delivery carriers for immunomodulatory molecules or peptides as immunomodulatory agents are especially welcome. Research papers that clearly demonstrate mechanistic studies of immunomodulatory pathways in vitro and in animal models using peptide-based therapeutics and/or theranostics - a personalized cancer treatment approach combining "therapeutics" and "diagnostics," as well as potentially translatable to human use and/or clinically (including phase 0-II clinical trials), are highly encouraged.

Learn more at https://ow.ly/aYnX50ZPEEt

10/16/2026

Why do we need support for basic science? Because successful drugs take decades to develop.

The FDA just approved a new drug for Parkinson’s disease that could help patients control symptoms with a once-daily pill. Tavapadon, sold under the name Juvmo, is expected to become available this month through AbbVie. The drug offers an alternative to levodopa, the gold standard treatment for some of the symptoms of Parkinson’s, and until now the only option for many patients.

The drug grew out of decades of research by Richard B. Mailman, a UVA School of Medicine professor of pharmacology and neuroscience, and Xuemei Huang, chair of UVA Health’s Department of Neurology, much of it published in ASPET’s Journal of Pharmacology and Experimental Therapeutics (https://jpet.aspetjournals.org/action/doSearch?type=quicksearch&text1=mailman&field1=AllField).

According to UVA Health, Dr. Mailman’s breakthrough came in 1984, when he recognized that existing drugs designed to activate dopamine receptors targeted a different group, called D2-like receptors. His experiments suggested that D1-like receptors accounted for most of levodopa’s benefits. He also suspected that targeting them would avoid many side effects associated with existing drugs of this type.

Every drug has a story. Every medication we take to improve our health or our lives is the result of years or decades of work by scientists.

ASPET congratulates Dr. Mailman, Dr. Huang, and all the researchers who contributed to the development of this drug. We hope it leads to a new era in treatment for people with Parkinson’s disease.

🔗News story: https://www.fauquiernow.com/news/fda-approves-parkinsons-drug-based-on-university-of-virginia-research-21d3d710

The FDA has approved Juvmo, a once-daily Parkinson’s pill developed from decades of University of Virginia research, with AbbVie expected to make it available t...

10/15/2026

ASPET Discovery is planning a new special collection titled “Advancing Pharmacology Education: Innovations, Evidence, and Emerging Directions.”

Submissions addressing the teaching and learning of pharmacology across biomedical science, medicine, pharmacy, nursing, dentistry, veterinary medicine, physician assistant/associate education, and other health professions are encouraged, as are studies focused on graduate and postgraduate education.

The deadline is April 15, 2027. Learn more about this special collection, and submit your work, at: https://ow.ly/fEOL50ZXz95

10/14/2026

This Drug Metabolism and Disposition special collection will highlight the critical need to understand novel mechanisms of action, PK/PD relationships, and safety considerations associated with emerging therapeutic platforms and bridge the gaps between advanced molecular engineering in pharmaceutics and rigorous translational ADME (absorption, distribution, metabolism, and excretion) science.

Learn more and submit your work: https://ow.ly/P6ie50ZVTFA

10/14/2026

Samantha Serna, a PhD Candidate at the University of Utah, is the Molecular Pharmacology Highlighted Trainee Author for October 2026.

Serna’s published work aims to mitigate respiratory irritation or damage caused by inhaled environmental pollutants, such as wood smoke and cigarette smoke, through kinase inhibitor-based pharmacological intervention.

"I hope my research will provide further insight into respiratory and environmental toxicology and help advance the field of pharmacological interventions in response to these stressors,” she shared.

➡️ Read the research here: https://doi.org/10.1016/j.molpha.2026.100153

10/14/2026

📅 TOMORROW: Join us in Philadelphia for an interactive workshop and happy hour.

Have you ever struggled with a promising idea that just seemed to go nowhere? You're not alone. We've all heard about the finished products and the success stories, but rarely talk about the failures along the way. From unexpected experimental results to unsuccessful clinical trials and shifts in funding priorities, setbacks are an inevitable part of developing new therapies. The ability to learn from these experiences, adapt, and move forward is a hallmark of successful scientists and leaders.

We've built an interactive workshop around the ways scientists at pharmaceutical and biotechnology organizations transform setbacks into opportunities for growth. Through real-world case studies, engaging presentations, and facilitated discussions, you will examine the factors that contribute to project setbacks and distinguish productive failures from preventable ones. You'll also take part in a networking reception with opportunities to connect with industry and biotechnology professionals.

This program will take place Thursday, Oct. 15 at The Study at University City (20 S. 33rd Street Philadelphia, PA 19104). While it is held in conjunction with the annual meeting of the Mid-Atlantic Pharmacology Society on Oct. 16, a separate registration is required. Learn more and register at https://www.aspet.org/aspet/meetings-awards/other-meetings/turning-setbacks-into-strategies--lessons-from-pharma-and-biotech

10/13/2026

ASPET is pleased to announce that Dr. Nina Isoherranen has been selected to succeed Dr. Xinxin Ding as Editor-in-Chief of Drug Metabolism and Disposition, effective January 1, 2027.

Dr. Isoherranen’s main research interests relate to vitamin A disposition and disease-retinoid interactions, pregnancy-mediated changes in drug disposition, and drug-drug interactions. Recently, her laboratory has made significant advances in characterization of drug-protein adducts by mass spectrometry.

Dr. Isoherranen has published over 180 peer reviewed manuscripts and eight book chapters, and holds three US patents. Read more about her research interests and background: https://ow.ly/xUpt50ZWOrg